Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Halcon Resources (NYSE: HK ) were flowing in the wrong direction today, falling as much as 15% after reporting earnings this morning.
So what: Results were mostly in line with estimates, as the shale explorer and producer delivered an adjusted EPS of $0.05 on expectations of $0.06. Without adjustments, however, profits were just $0.01 per share. Revenues, meanwhile, shot up more than 600%, in line with expectations, due to a variety of acquisitions. Lease operating expense also fell sharply by 47%.
Now what: The market seems to be excessively punishing Halcon for the earnings miss, which seems worse when looked at percentage-wise, as net income was about 20% below expectations. The market was perhaps expecting an earnings beat. That may look problematic, but the shale plays on which Halcon Resources are focused have serious growth potential. I wouldn't give up on Halcon just yet. You can keep track of all the latest developments by adding the company to your Watchlist here.
Top 5 Penny Companies To Watch In Right Now: Shire PLC (SHPG)
Shire plc (Shire), incorporated on January 28, 2008, is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI) diseases, human genetic therapies (HGT) and regenerative medicine (RM), as well as opportunities in other therapeutic areas. As of December 31, 2012, the Company�� products included VYVANSE/VENVANSE (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), FOSRENOL (lanthanum carbonate), XAGRID (anagrelide hydrochloride), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant) and DERMAGRAFT(Human Fibroblast-Derived Dermal Substitute). As of December 31, 2012, the Company�� products under development included INTUNIV (extended release guanfacine), VYVANSE/VENVANSE (lisdexamfetamine dimesylate), INTUNIV, Guanfacine Carrier Wave, LIALDA (mesalamine)/MEZAVANT (mesalazine), RESOLOR (prucalopride), RESOLOR (prucalopride), SPD 557(M0003), XAGRID, VYVANSE (lisdexamfetamine dimesylate), REPLAGAL (agalsidase alfa), HGT-4510, HGT-2310, HGT-1410, HGT-1110, HGT-3010, and DERMAGRAFT. On January 31, 2012, the United States Food and Drug Administration approved VYVANSE for the maintenance treatment of ADHD in adults. In March 2013, it announced the acquisition Of Premacure AB. In January 2014, Shire Plc sold its DERMAGRAFT assets to Organogenesis Inc. In January 2014, Shire Plc acquired 79.5% interest in ViroPharma Inc.
VANSE/ VENVANSE
VYVANSE is a New Chemical Entity (NCE) and is the pro-drug stimulant for the treatment of ADHD, where the amino acid l-lysine is linked to d-amphetamine. VYVANSE is therapeutically inactive until metabolized in the body. The United Stat! es Food and Drug Administration approved VYVANSE as a once-daily treatment for children aged 6 to 12 with ADHD in February 2007, for adults in April 2008 and for adolescents aged 13 to 17 in November 2010. VYVANSE is available in the United States in six dosage strengths: 20 milligram, 30 milligram, 40 milligram, 50 milligram, 60 milligram and 70 milligram. Health Canada approved VYVANSE for the treatment of ADHD in pediatric patients aged 6 to 12 in February 2009, and for adolescents and adults in November 2010. In April 2012, ANVISA, the Brazilian health authority, granted marketing authorization approval for lisdexamfetamine dimesylate for the treatment of ADHD in children aged 6-12.
ADDERALL XR
ADDERALL XR is an extended release treatment for ADHD, which uses MICROTROL drug delivery technology and is designed to provide once-daily dosing. It is available in 5 milligram, 10 milligram, 15 milligram, 20 milligram, 25 milligram and 30 milligram capsules and can be administered either as a capsule or sprinkled on soft food. The United States Food and Drug Administration has approved ADDERALL XR as a once-daily treatment for children aged 6 to 12 with ADHD, for adults in and for adolescents aged 13 to 17. Teva Pharmaceutical Industries, Ltd. (Teva) and Impax Laboratories, Inc. (Impax) commenced commercial shipment of their authorized generic versions of ADDERALL XR in April and October 2009, respectively. Shire receives royalties from Impax�� sales of authorized generic ADDERALL XR.
INTUNIV
INTUNIV is a selective alpha-2A receptor agonist indicated for the treatment of ADHD. Alpha-2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signalling in the prefrontal cortex (Cell. 2007; 129:397-410). INTUNIV is non-scheduled and has no known potential for abuse or dependence. The United States Food and Drug Administration approved INTUNIV in September 2009, as a once-daily monotherapy treatment of ADHD in children and adolesce! nts aged ! 6 to 17. It is available in 1 milligram, 2 milligram, 3 milligram and 4 milligram tablets.
EQUASYM
Shire has acquired from UCB the worldwide rights (excluding the United States, Canada and Barbados) to EQUASYM (methylphenidate hydrochloride) IR and XL for the treatment of ADHD in children and adolescents aged 6 to 18. At December 31, 2012,EQUASYM XL was commercially available in 10 countries in 10mg, 20mg and 30mg strengths. EQUASYM XL is marketed in Mexico and South Korea under the trade name METADATE CD.
LIALDA/MEZAVANT
LIALDA is indicated for the induction ofmild to moderately active UC and for the maintenance of remission of UC. The addition of the indication for maintenance of remission of ulcerative colitis was approved by Health Canada in February 2011, and by the United States Food and Drug Administration in July 2011. LIALDA is once-daily oral formulation of mesalamine indicated for the induction and maintenance of remission. As of December 31, 2012, LIALDA/MEZAVANT (this product is marketed outside the United States as MEZAVANT) was commercially available in 19 countries either directly or through distributor arrangements.
PENTASA
PENTASA controlled release capsules are approved in the United States (marketed by Shire in the United States and by Ferring outside of the United States) and indicated for the induction of remission and for the treatment of patients with mild to moderately active ulcerative colitis. PENTASA is an ethylcellulose-coated, controlled release capsule formulation designed to release therapeutic quantities of mesalamine throughout the gastrointestinal tract. PENTASA is available in the United States in 250 milligram and 500 milligram capsules.
RESOLOR
RESOLOR (prucalopride), a 5-HT4 receptor agonists that stimulates gastrointestinal motility and acts primarily on different parts of the lower gastrointestinal tract (enterokinetic). In October 2009, RESOLOR was appr! oved by t! he EMA throughout the European Union as a once daily oral treatment for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. In July 2010, Swissmedic granted RESOLOR marketing authorization in Switzerland for the treatment of idiopathic chronic constipation in adults. RESOLOR is available in milligram and 2 milligram dose strengths, both for once-daily dosing. At December 31, 2012, RESOLOR was available in six European Union countries. Formulated as a chewable tablet, FOSRENOL is available in 500 milligram, 750 milligram and 1,000 milligram dosage strengths.
XAGRID
XAGRID (anagrelide hydrochloride) is marketed in Europe for the reduction of elevated platelet counts in at-risk ET patients. XAGRID has been granted orphan drug status in the European Union. In the United States, anagrelide hydrochloride is sold by the Company under the name AGRYLIN for the treatment of thrombocythemia secondary to a MPD.
REPLAGAL
REPLAGAL is for the treatment of Fabry disease. Fabry disease is a genetic disorder resulting from a deficiency in the activity of the lysosomal enzyme alpha-galactosidase A, which is involved in the breakdown of fats. REPLAGAL is a human alpha-galactosidase A protein made in human cells that replaces the deficient alpha-galactosidase A with an active enzyme to ameliorate certain clinical manifestations of Fabry disease. At December 31, 2012, REPLAGAL was approved in 46 countries.
ELAPRASE
ELAPRASE is a treatment for Hunter syndrome (also known as Mucopolysaccharidosis Type II or MPS II). Hunter syndrome is a genetic disorder mainly affecting males that interferes with the body's ability to break down and recycle waste substances called mucopolysaccharides, also known as glycosaminoglycans (GAGs). ELAPRASE was approved by the United States Food and Drug Administration and granted marketing authorization by the EMA for the long term treatment of patients with Hunter ! syndrome.! ELAPRASE has been granted orphan drug by both the United States Food and Drug Administration and the EMA. ELAPRASE received approval from the Ministry of Health, Labour and Welfare in Japan. At December 31, 2012, ELAPRASE was approved in 51 countries.
VPRIV
VPRIV is a treatment for Type 1 Gaucher disease. Gaucher disease is an inherited genetic disorder, which results in a deficiency of the lysosomal enzyme beta-glucocerebrosidase. VPRIV was approved by the United States Food and Drug Administration in February 2010, for the long-term treatment of patients with Type 1 Gaucher disease. The EMA approved the marketing authorization for the use of VPRIV in August 2010. VPRIV was authorized as an orphan medicine through the Centralised Procedure in Europe. At December 31, 2012, VPRIV was approved in 38 countries.
FIRAZYR
FIRAZYR is a peptide-based therapeutic developed for the symptomatic treatment of acute attacks of HAE. In July 2008 the EMA granted marketing authorization throughout the European Union for the use of FIRAZYR for the symptomatic treatment of acute attacks of HAE, and in May 2011 approved FIRAZYR for self-administration after training in subcutaneous injection technique by a healthcare professional. In August 2011, the United States Food and Drug Administration granted marketing approval for FIRAZYR in the United States for treatment of acute attacks of HAE in adults aged 18 and older. After injection training, patients may self-administer FIRAZYR. FIRAZYR has been granted orphan drug by both the United States Food and Drug Administration and the EMA. At December 31, 2012, FIRAZYR was approved in 38 countries globally.
DERMAGRAFT
DERMAGRAFT is a bio-engineered skin substitute that assists in restoring damaged tissue. DERMAGRAFT is indicated for use in the treatment of full-thickness Diabetic foot ulcers (DFU) greater than six weeks in duration, which extend through the dermis, but without tendon, muscle, joint capsu! le, or bo! ne exposure. DERMAGRAFT is approved by the United States Food and Drug Administration as a Class III medical device for the treatment of DFUs. DERMAGRAFT is also approved for the treatment of DFUs in South Africa, Israel and Singapore.
The Company competes with Shionogi & Co., Ltd., Janssen-Cilag, Novartis, Medice, Eli Lilly, Warner Chilcott, Synergy Pharmaceuticals, Inc., ARYx Therapeutics, Theravance, Inc., Sucampo Pharmaceuticals, Inc., Albireo, Actelion Ltd., Protalix BioTherapeutics Inc, Genzyme, CSL Behring, Pharming Group N.V., ViroPharma, Dyax Corporation, Organogenesis, Healthpoint, Soluble System, KCI, Smith & Nephew, Aurobindo and Apotex.
Advisors' Opinion:- [By MONEYMORNING.COM]
Several recent high-profile tax inversions, such as AbbVie Inc.'s (NYSE: ABBV) merger with Ireland-based Shire Plc. (Nasdaq ADR: SHPG) and Medtronic Inc.'s (NYSE: MDT) deal to buy Ireland-based Covidien Plc. (NYSE: COV), have resulted in much wailing and gnashing of teeth in our nation's capital.
- [By Eddie Staley]
AbbVie (NYSE: ABBV) lifted its offer to buy Shire plc (NASDAQ: SHPG) to 30.1 billion pounds ($51.3 billion).
The latest offer for Shire is approximately an 11 percent increase from the previous bid. The new offer stands at £22.44 cash and 0.8568 AbbVie shares for each Shire share, or £51.15 total.
- [By MONEYMORNING.COM]
Recently these deals have been focused on the pharmaceutical and healthcare industries, and stocks in those industries took a dive after the Treasury released its new regulations on Monday. British pharmaceutical giant AstraZeneca Plc. (NYSE ADR: AZN), which had been the target of a failed inversion bid by U.S. drug maker Pfizer Inc. (NYSE: PFE), dropped 3.6%. AbbVie Inc. (NYSE: ABBV), which is involved in a $54 billion deal to buy Irish pharmaceutical giant Shire Plc. (Nasdaq ADR: SHPG), was down 1.9%. Covidien Plc. (NYSE: COV), an Irish company being bought by American medical device maker Medtronic Inc. (NYSE: MDT) was down 3%.
Top Income Stocks To Watch For 2014: Esco Technologies Inc (ESE)
ESCO Technologies Inc. (ESCO), incorporated in August 1990, is a producer of engineered products and systems sold to customers worldwide, primarily for utility, industrial, aerospace and commercial applications. ESCO operates in three segments: Utility Solutions Group (Utility Solutions), RF Shielding and Test (Test) and Filtration/Fluid Flow (Filtration). On July 31, 2010, the Company acquired the capital stock of Crissair, Inc. On September 3, 2010, the Company acquired the capital stock of Xtensible Solutions, Inc. its subsidiaries include Aclara Power-Line Systems Inc. (Aclara PLS), Aclara RF Systems Inc. (Aclara RF), Aclara Software Inc., Doble Engineering Company, Doble Lemke AG, Doble Lemke GmbH, Doble PowerTest Limited, Doble TransiNor AS, Crissair, Inc., PTI Technologies Inc., TekPackaging LLC, VACCO Industries, Beijing Lindgren ElectronMagnetic Technology Co., Ltd., ETS-Lindgren L.P., ETS-Lindgren OY, ETS Lindgren Limited and ETS Lindgren Japan, Inc. In January 2013, the Company acquired the assets of Metrum Technologies LLC. In June 2013, ESCO Technologies Inc announced that it has acquired Canyon Engineering Products Inc.
UTILITY SOLUTIONS
The Utility Solutions segment accounted for approximately 57% of the Company�� total revenue during the fiscal year ended September 30, 2010 (fiscal 2010). Aclara PLS is a manufacturer of two-way power line communication systems for the electric utility industry (the TWACS systems), which are composed of equipment (meter modules and equipment for central stations and substations), software and support services. The TWACS systems provide electric utilities with a communication technology for automatic meter reading, load control, interval data, outage assessment/restoration monitoring, remote service disconnect/connect, time-of-use data for critical peak pricing, tamper/theft detection and pre-paid metering. Revenue from the TWACS systems accounted for approximately 22% of the Company�� total revenue in fiscal 2010. Aclara R! F provides, through its STAR network, wireless radio frequency (RF) data communications systems to gas, water and electric utilities for advanced metering infrastructure (AMI) applications. In fiscal 2010, total revenue received by the Company from PG&E for all sales was 9.2% of the Company�� consolidated revenue. Revenue from STAR network products, accounted for approximately 17%, of the Company�� total revenue in fiscal 2010.
Aclara Software Inc. provides utilities with software systems for energy and water information, delivering a scalable meter data management system (MDMS), AMI/meter device records and asset management, business applications addressing areas, such as revenue assurance and distribution asset analysis. Aclara�� analytics-based software applications are used by over 100 energy organizations worldwide. Doble provides electric utility customers with products and services to achieve the reliability and sustainability of electric power infrastructure. It combines three elements for customers: diagnostic test instruments, expert consulting and testing services. Revenue from Doble�� products and services, accounted for approximately 15%, of the Company�� total revenue in fiscal 2010.
TEST
The Test segment accounted for approximately 23% of the Company�� total revenue in fiscal 2010. ETS-Lindgren designs and manufactures products to measure and contain magnetic, electromagnetic and acoustic energy. It supplies customers with a range of isolated environments including RF test enclosures, acoustic test enclosures, RF and magnetically shielded rooms, secure communication facilities and broadcast and recording studios. these facilities include shielded doors and windows. ETS-Lindgren also provides the design, program management, installation and integration services required to complete these types of facilities. ETS-Lindgren also supplies customers with a range of components, including RF absorptive materials, RF filters, active compensatio! n systems! , antennas, antenna masts, turntables and electric and magnetic probes, RF test cells, measurement software and other test accessories required to perform a variety of tests. ETS-Lindgren also offers a variety of services, including calibration for antennas and field probes, chamber certification, field surveys, customer training and a variety of product tests.
FILTRATION
The Filtration segment accounted for approximately 20%, of the Company�� total revenue in fiscal 2010. PTI is a supplier of filtration products serving the commercial aerospace, military aerospace and various industrial markets. The industrial markets include chemical processing, automotive and mobile equipment. Products include filter elements, assemblies, modules, indicators and other related components. VACCO supplies flow control products, valves and filters to the space, defense and commercial industries for use in aircraft, satellite propulsion systems, satellite launch vehicles and other space transportation systems, such as the Space Shuttle and its successor. VACCO also uses its etched disc technology to produce quiet valves and manifolds for the United States Navy applications. Crissair, Inc. supplies a variety of custom and standard valves and other various components to the aerospace, defense and commercial industries. Platform applications include fixed and rotary wing aircraft, air transport and business jets, and defense systems. TekPackaging LLC produces thermoformed products and packaging materials for medical, retail, food and electronic applications.
The Company competes with Itron, Inc., Silver Spring Networks, Landis+Gyr, Cannon Technologies Inc., Sensus Metering Systems Inc., Trilliant Inc., Elster Electricity, L.L.C., Comverge, Inc., Neptune Technology Group, e-Meter Corporation, Oracle Corporation, APOGEE Interactive Inc., Opower, Inc., Ecologic Analytics, LLC, SmartSynch, Inc.,Tantalus Systems Corp, OMICRON Electronics Corp. USA, OMICRON, Megger Group Limited, EM shiel! ding mark! et, TDK RF Solutions Inc., Albatross GmbH, IMEDCO AG, Cuming Corporation, Pall Corporation, Moog, Inc., SoFrance and Clarcor Inc.
Advisors' Opinion:- [By James Miller Phd]
Pall Corporation (PLL) is a supplier of filtration, separation and purification technologies, principally made by the company, for the removal of solid, liquid and gaseous contaminants from a range of liquids and gases. The company serves customers through two businesses globally: Life Sciences and Industrial. While Pall competes with many companies in the Life Sciences markets and Industrial, few companies operate in both, like ESCO Technologies Inc. (ESE) and Danaher Corp. (DHR).
Top Income Stocks To Watch For 2014: New Oriental Education & Technology Group Inc.(EDU)
New Oriental Education & Technology Group Inc. provides private educational services primarily in the People?s Republic of China. It offers a range of educational programs, services, and products consisting primarily of English and other foreign language training; test preparation courses for admissions and assessment tests; primary and secondary school education; development and distribution of educational content; software and other technology; and online education. The company?s language training courses primarily consist of various types of English language training courses, and other foreign languages, including German, Japanese, French, Korean, and Spanish. It offers test preparation courses for language and entrance exams used by educational institutions in the United States, the People?s Republic of China, and commonwealth countries. The company also operates primary and secondary schools in Yangzhou. In addition, New Oriental Education & Technology Group Inc. deve lops and edits content for educational materials for language training and test preparation, such as books, software, CD-ROMs, magazines, and other periodicals. It distributes these materials through various distribution channels consisting of own classrooms and bookstores, as well as third-party distributors. Further, the company offers various online education programs on its Web site, koolearn.com. Additionally, it provides consulting services to help students through the application and admission process for overseas educational institutions, as well as post-secondary educational programs to help students seek career opportunities; and operates two pre-schools. The company offers educational services under the ?New Oriental? brand name. As of May 31, 2010, it offered education programs, services, and products through a network of 48 schools, 319 learning centers, and 25 bookstores. The company was founded in 1993 and is headquartered in Beijing, the People?s Republic of China.
Advisors' Opinion:- [By Belinda Cao]
New Oriental Education & Technology Group Inc. (EDU), China�� largest private educational company, fell 11 percent last week to a one-month low of $16.07. Oppenheimer & Co. analyst Ella Ji said April 2 that students may avoid large gatherings because of the flu, impacting New Oriental.
- [By Jake L'Ecuyer]
Equities Trading DOWN
Shares of New Oriental Education & Technology Group (NYSE: EDU) were 8.55 percent to $23.76 after the company reported FQ3 results. New Oriental's quarterly net income surged 50.2% y/y to US$42.1 million versus US$28.0 million. - [By Seth Jayson]
New Oriental Education & Technology Group (NYSE: EDU ) reported earnings on April 24. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Feb. 28 (Q3), New Oriental Education & Technology Group met expectations on revenues and beat expectations on earnings per share. - [By Jake L'Ecuyer]
Equities Trading DOWN
Shares of New Oriental Education & Technology Group (NYSE: EDU) were 9.62 percent to $23.48 after the company reported FQ3 results. New Oriental's quarterly net income surged 50.2% y/y to US$42.1 million versus US$28.0 million.
Top Income Stocks To Watch For 2014: iShares MSCI Russia Capped ETF (ERUS)
iShares MSCI Russia Capped ETF (the Fund), formerly iShares MSCI Russia Capped Index Fund,, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the MSCI Russia 25/50 Index (the Underlying Index). The Underlying Index is a free-float adjusted market capitalization weighted index designed to measure the performance of equity securities in the top 85% by market capitalization of equity securities listed on stock exchanges in Russia. The Underlying Index is a customized variation of the MSCI Russia Index, designed to cap certain weightings to take into account the investment diversification requirement applicable to regulated investment companies. The Fund�� investment advisor is BlackRock Fund Advisor. Advisors' Opinion:- [By Barbara Kollmeyer]
As for U.S. investor exposure, the pain was there for all to see as the week wound down. Among exchange-traded funds, the iShares MSCI Russia ETF (ERUS) �and the SPDR S&P Russia ETF (RBL) �each fell more than 6% for the week, contrasting with a 0.1% gain for the iShares MSCI Emerging Markets ETF (EEM) .
- [By Charles Sizemore]
But what exactly are you buying when you buy Russian stocks? Let�� take a look under the hood at the ETFs that track the Russian market: the Market Vectors Russia ETF (RSX), the iShares MSCI Russia Capped Index (ERUS) and the SPDR S&P Russia (RBL).
No comments:
Post a Comment